What is AHK-Cu?

AHK-Cu is the copper complex of the tripeptide alanine-histidine-lysine. It sits in the same broad copper-peptide family as GHK-Cu, but the first amino acid differs: AHK begins with alanine, while GHK begins with glycine.[1][2][3]

The direct AHK-Cu literature is much narrower than the GHK-Cu literature. Its anchor study used isolated human hair follicles and cultured dermal papilla cells, which makes it useful for hair-follicle biology but not enough to claim proven hair regrowth in people.[1][5]

The biological reason people care is straightforward: dermal papilla cells help control the hair-growth cycle, and AHK-Cu is linked with follicle elongation, dermal papilla cell proliferation, and anti-apoptotic markers. In plain terms, it points to a follicle-support signal under laboratory conditions.[1]

AHK-Cu should not be collapsed with GHK-Cu or Pal-AHK. GHK-Cu is the better-studied copper tripeptide for skin remodeling, while Pal-AHK is a palmitoylated derivative designed for topical delivery. Related structure does not make the evidence interchangeable.[1][2][4]

What AHK-Cu is investigated for

AHK-Cu evidence is grouped by practical use case and topical route context.Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Hair follicle elongation

Topical

30%Limited

AHK-Cu has an ex vivo follicle-elongation signal, but proven topical hair regrowth in people has not been shown.[1]

Human evidence

No controlled human scalp outcome trial was identified for AHK-Cu. The available follicle-elongation evidence uses isolated human follicles outside the body, not topical use in people.[1][6]

Animal / mechanistic evidence

AHK-Cu stimulated elongation of human hair follicles ex vivo at laboratory concentrations.[1]

Dermal papilla cell proliferation

Topical

30%Limited

Dermal papilla cell proliferation is a plausible hair-growth mechanism, but clinical hair-loss efficacy has not been established.[1]

Human evidence

No finished-product human scalp trial was identified that shows AHK-Cu increases dermal papilla cell activity in vivo.[6][1]

Animal / mechanistic evidence

Cultured dermal papilla cells showed proliferation with AHK-Cu; this follicle-cell population is involved in hair-cycle signaling.[1]

Hair-follicle cell survival signaling

Topical

28%Limited

Hair-follicle cell-survival signaling is plausible follicle support, but anti-shedding or hair-restoration outcomes remain unproven.[1]

Human evidence

No controlled human outcome source shows that AHK-Cu reduces follicle-cell apoptosis on the scalp.[6]

Animal / mechanistic evidence

AHK-Cu shifted anti-apoptotic markers in dermal papilla cells, including a higher Bcl-2/Bax ratio and lower cleaved caspase-3 and PARP measures.[1]

VEGF and TGF-beta skin signaling

Topical

28%Limited

VEGF and TGF-beta changes are laboratory signals for skin and follicle biology; human skin-repair or anti-aging outcomes are not established.[1]

Human evidence

No controlled human topical AHK-Cu clinical trial was identified for skin vascular signaling, wrinkle appearance, or wound outcomes.[6]

Animal / mechanistic evidence

Dermal fibroblast laboratory models showed proliferation, elevated VEGF production, and reduced TGF-beta1 secretion with AHK-Cu.[1]

Collagen type I support

Topical

26%Limited

Collagen type I support has AHK-Cu laboratory evidence, but topical collagen remodeling in people has not been established.[1][2]

Human evidence

No controlled human AHK-Cu topical skin-aging or collagen-density outcome trial was identified.[6][2]

Animal / mechanistic evidence

Dermal fibroblast laboratory models showed increased collagen type I production with AHK-Cu.[1]

Evidence snapshot

Overall confidence

Limited

42%

The AHK-Cu evidence base is narrow but concrete: one direct human-follicle laboratory paper plus broader copper-peptide and cosmetic-peptide literature. Human scalp outcomes remain unproven.[1][5][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

12%

Human evidence

Insufficient

No controlled human scalp outcome trial was identified for AHK-Cu under the reviewed ingredient names.[1][6]

36%

Animal / preclinical

Limited

Preclinical support is concentrated in one ex vivo and cell-culture human-follicle paper. It reported follicle elongation, dermal papilla proliferation, anti-apoptotic markers, VEGF and TGF-beta changes, and collagen type I production, but no finished-product scalp outcomes.[1]

38%

Mechanism support

Limited

The lab signal includes follicle elongation, dermal papilla cell proliferation, and anti-apoptotic markers, which supports plausibility without proving clinical regrowth.[1]

Forms & administration

AHK-Cu fits best as a topical/scalp cosmetic ingredient. Injection, mesotherapy, and drug-treatment claims should not be inferred from the current AHK-Cu evidence base.[1][4][7]

Topical

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Topical amounts follow the product label. Injectable protocols use about 250 mcg per dose.[1][4]

Frequency

Topical and injectable protocols are usually once daily.[5][4]

Timing Considerations

Topical use is usually in the evening. Injections are usually taken in the morning.[4]

Cycle Length

Topical use is ongoing. Injectable cycles commonly run 4 weeks.[5][1]

What to expect

First 1-2 weeks

Scalp feel: calmer-feeling scalp, easy absorption, manageable residue, and a routine that fits daily use.[4][5]

Weeks 8-12

Subtle hair-cosmetic changes: steadier shedding patterns, slightly better hair feel, or a fuller-looking part line in consistent photos.[1][5]

Months 3-6

Gradual hair-cycle changes: reduced visible scalp, improved hair caliber, or more stable shedding patterns alongside the rest of the routine.[5][1]

After stopping

Scalp feel, shedding pattern, or visible density may gradually drift back toward baseline as the topical routine drops out, with hair-cycle changes moving slowly rather than day to day.[5][1]

Safety profile

AHK-Cu safety is best handled as topical cosmetic safety plus evidence gaps. Monitor scalp irritation and product tolerability; do not infer injectable or disease-treatment safety from the current literature.[4][7][1]

Common side effects

Scalp redness[4]
Itching or burning[4]

Cautions

Open or inflamed scalp[7]
Injectable use[8][7]

What we don't know

Human scalp efficacy, topical pharmacokinetics, ideal concentration, long-term scalp safety, pregnancy safety, and interaction data remain unresolved.[1][6]

Who AHK-Cu is not for

Route-specific avoid and medical-review notes:

Active scalp disease or open skin
Use medical review first for infection, open lesions, severe dermatitis, psoriasis flares, unexplained hair loss, or sudden shedding.[7][5]
Pregnancy, breastfeeding, or pediatric use
Dedicated AHK-Cu safety data are not established for pregnancy, breastfeeding, or pediatric cosmetic use.[4]
Known cosmetic ingredient sensitivity
People with previous reactions to peptide, copper-complex, preservative, fragrance, or solvent systems should treat new AHK-Cu products cautiously.[4]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Other irritating scalp actives
Layering AHK-Cu with minoxidil vehicles, retinoids, acids, dyes, harsh shampoos, or microneedling can make irritation harder to interpret.[4][5]
Additional copper peptides
Using several copper-peptide products at once can make irritation, staining, or tolerability attribution unclear; combination evidence is not established.[2][4]

Regulatory status

United States

United States: no FDA-approved AHK-Cu drug product was identified in the reviewed openFDA query. Topical cosmetic scalp products are regulated separately from drugs; hair-loss treatment claims can create drug claims.[8][7]

Route	FDA drug approval	503A compounding
Topical	Not Approved openFDA Drugs@FDA queries for AHK-Cu and Copper Tripeptide-3 returned no matching approved drug product. Cosmetic scalp products are separate from therapeutic hair-loss drug claims.[8][7]	Not Listed The current 503A bulk-substances PDF review did not identify AHK-Cu or Copper Tripeptide-3 as a listed nominated substance. That absence does not turn cosmetic availability into drug approval.[9]

Topical

FDA drug approval

Not Approved

openFDA Drugs@FDA queries for AHK-Cu and Copper Tripeptide-3 returned no matching approved drug product. Cosmetic scalp products are separate from therapeutic hair-loss drug claims.[8][7]

503A compounding

Not Listed

The current 503A bulk-substances PDF review did not identify AHK-Cu or Copper Tripeptide-3 as a listed nominated substance. That absence does not turn cosmetic availability into drug approval.[9]

International

International status is market-, product-, and claim-specific. EU/Europe, the UK, Canada, and Australia regulate cosmetic products through cosmetic or industrial-chemical frameworks, while therapeutic hair-loss claims may trigger medicine or drug rules.[10][11][12][13]

Sports & competition

Topical cosmetic AHK-Cu has no specific anti-doping issue identified in the reviewed materials. Systemic or injectable use is not athlete-cleared, and non-approved-substance logic can matter when a product is used as an unapproved drug.[14][8]

How it works

The dermal papilla is a signaling hub at the base of the hair follicle. AHK-Cu is mechanistically interesting because its lab signal involves this follicle compartment rather than only generic skin fibroblasts.[1]

Follicle elongation and dermal papilla cell activity make AHK-Cu mechanistically plausible for scalp support. That is a lower-confidence statement than saying it treats hair loss.[1]

The copper-peptide family relationship helps explain why AHK-Cu gets compared with GHK-Cu, but GHK-Cu's skin-remodeling evidence should not be copied into AHK-Cu hair claims.[1][2]

Research gaps & open questions

What the current literature has not yet settled about AHK-Cu:

Controlled scalp trials in people still need to show whether AHK-Cu meaningfully slows hair loss or improves hair growth.[1][6]

Finished-product studies should show whether topical formulas deliver enough AHK-Cu to the hair follicle to have an effect.[4][1]

Direct comparisons should test whether adding AHK-Cu improves results beyond established hair-loss treatments alone.[5][1]

AHK-Cu, GHK-Cu, and Pal-AHK need direct comparisons; results from one copper peptide should not be assumed to apply to the others.[1][2][4]

Common questions

Is AHK-Cu the same as GHK-Cu?

No. Both are copper tripeptides, but AHK-Cu has alanine in the first position and a much narrower hair-follicle evidence base, while GHK-Cu has broader skin-remodeling literature.[1][2]

Is AHK-Cu clinically proven to regrow hair?

No. The direct evidence is an ex vivo and in vitro human hair-follicle study, not a controlled human scalp trial.[1][6]

Is AHK-Cu topical or injectable?

AHK-Cu is best treated as a topical/scalp cosmetic ingredient. Injectable or mesotherapy use has no established clinical basis in the reviewed sources and should not be inferred from cosmetic products.[7][8]

Can AHK-Cu replace minoxidil or prescription hair-loss treatment?

No. AHK-Cu is a preclinical follicle-support ingredient, not an evidence-based replacement for established medical hair-loss therapies.[1][8]

Is AHK-Cu the same as Pal-AHK?

No. AHK-Cu is the copper complex, while Pal-AHK is a palmitoylated derivative discussed for cosmetic delivery. Their evidence should be reviewed separately.[1][4]

Myths & misconceptions

Myth

AHK-Cu is a clinically proven hair-loss treatment.

Reality

Isolated follicles and cultured dermal papilla cells show meaningful follicle biology, but they are not a controlled human hair-loss trial.[1]

Myth

AHK-Cu can use the same evidence score as GHK-Cu.

Reality

The family relationship is real, but GHK-Cu's skin-remodeling evidence does not prove AHK-Cu scalp outcomes.[1][2]

Myth

Injecting AHK-Cu into the scalp works better than topical use.

Reality

Injectable AHK-Cu is not supported by the reviewed evidence and cosmetic products are not sterile injectable medicines.[7][8]

History & discovery

AHK-Cu entered the hair-peptide conversation through a 2007 laboratory study using isolated human hair follicles and dermal papilla cells, then spread into cosmetic scalp-product and copper-peptide discussions.[1][5]

Pyo and colleagues reported that AHK-Cu stimulated elongation of isolated human hair follicles and proliferation of cultured dermal papilla cells.[1]

Cosmetic and hair anti-aging reviews discussed peptides, copper tripeptides, and topical hair-support ingredients, while emphasizing the broader problem of limited randomized clinical evidence for many cosmetic peptides.[4][5]

Published research14 studies

[1]

The effect of tripeptide-copper complex on human hair growth in vitro.

PubMed / Archives of Pharmacal Research, 2007-07. ex vivo.

[2]

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.

PubMed / BioMed Research International, 2015. review.

[3]

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.

PubMed / International Journal of Molecular Sciences, 2018-07-07. review.

[4]

Usage of Synthetic Peptides in Cosmetics for Sensitive Skin.

PubMed / Pharmaceuticals, 2021-07-21. review.

[5]

Topical and nutricosmetic products for healthy hair and dermal antiaging using dual-acting plant-based peptides, hormones, and cannabinoids.

PubMed / FASEB BioAdvances, 2021-08. review.

[6]

ClinicalTrials.gov query for AHK-Cu and Copper Tripeptide-3

ClinicalTrials.gov. clinical trial registry.

[7]

FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated

U.S. Food and Drug Administration, 2025-11-20. official guidance.

[8]

openFDA Drugs@FDA query for AHK-Cu and Copper Tripeptide-3

openFDA / U.S. Food and Drug Administration. database query.

[9]

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act

U.S. Food and Drug Administration, 2026-05-14. regulatory.

[10]

Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products

EUR-Lex. official guidance.

[11]

Making cosmetic products available to consumers in Great Britain

UK Office for Product Safety and Standards. official guidance.

[12]

Cosmetics regulatory information

Health Canada. official guidance.

[13]

Cosmetics and soap

Australian Industrial Chemicals Introduction Scheme. official guidance.

[14]

2026 Prohibited List: International Standard

World Anti-Doping Agency, 2025. official guidance.